✦ LIBER ✦

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial

✍ Scribed by Hu, Zhihuang; Cheng, Ying; Zhang, Hongyu; Zhou, Caicun; Han, Baohui; Zhang, Yiping; Huang, Cheng; Chang, Jianhua; Song, Xiangqun; Liang, Jun; Liang, Houjie; Bai, Chunxue; Yu, Shiying; Chen, Jia; Wang, Jie; Pan, Hongming; Chitkara, Denesh K.; Hille, Darcy A.; Zhang, Li

Book ID: 121535659
Publisher: Springer-Verlag
Year: 2013
Tongue: English
Weight: 347 KB
Volume: 22
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-013-2043-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

687 The oral NK1 antagonist aprepitant f

687 The oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: pooled data from 2 randomized, double-blind, placebo controlled trials

✍ R. Gralla; P. Hesketh; S. Grunberg; D. Warr; F. Roila; S. Chawla; A. Carides; K. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Single-Dose Fosaprepitant for the Preven

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol--EASE

✍ Grunberg, S.; Chua, D.; Maru, A.; Dinis, J.; DeVandry, S.; Boice, J. A.; Hardwic 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 152 KB

Olanzapine for the Prevention of Chemoth

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study

✍ Mizukami, Naomi; Yamauchi, Masanori; Koike, Kazuhiko; Watanabe, Akihiko; Ichihar 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 243 KB

O-249 Evaluation of the efficacy and tol

O-249 Evaluation of the efficacy and tolerability of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: two randomized, double-blind, placebo controlled trials

✍ Gralla, Richard J.; Hesketh, Paul J.; Grunberg, Steven M.; Warr, David G.; Roila 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Addition of the neurokinin 1 receptor an

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting : Results from a randomized, double-blind, placebo-controlled trial in Latin America

✍ Sergio Poli-Bigelli; Jose Rodrigues-Pereira; Alexandra D. Carides; Guoguang Juli 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

Efficacy and safety of casopitant mesyla

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

✍ Steven M Grunberg; Janusz Rolski; Janos Strausz; Zeba Aziz; Stephen Lane; Mark W 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 251 KB